US/EU orphan status for BI’s Ofev in systemic sclerosis
US and EU regulators have granted Orphan Drug Designation to Boehringer Ingelheim’s Ofev for the treatment of systemic sclerosis, including the associated interstitial lung disease.
Read More
Tag: systemic sclerosis
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
